Compare Quest Diagnostics Inc (DGX) vs Nike Inc (NKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Nike Inc — how do they compare? Quest Diagnostics Inc trades at $239.17 (market cap $26.24B), while Nike Inc trades at $40.67 (market cap $60.10B). The key difference: Nike Inc is far larger — about 2.3× Quest Diagnostics Inc's market cap, and Nike Inc pays the higher dividend (4.05%). Which is the better fit depends on your goals.
| DGX | NKE | |
|---|---|---|
Market Cap | $26.24B | $60.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $238.50 | $79.17 |
52-Week Low | $173.49 | $40.51 |
Enterprise Value | $32.00B | $62.10B |
Dividend Yield | 1.45% | 4.05% |
Volume | — | 8,887,180 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Nike (NKE) trades at $41.32, down 1.88% on the day, reflecting ongoing investor caution amid revenue declines and margin pressures. Recent earnings beats have not offset concerns over sales weakness in key markets like China. Technical indicators are bearish, with the stock testing support near $41. The company maintains strong brand equity but faces execution risks in its turnaround strategy.
The outlook hinges on Nike's ability to stabilize revenue and improve margins through its 'Win Now' initiatives. Near-term catalysts include the Q4 2026 earnings report on June 30, 2026. Risks include persistent demand softness and competitive pressures, while the consensus price target of $50.45 suggests 22% upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
